|
EP0170269A3
(en)
|
1984-08-02 |
1987-09-23 |
Kao Corporation |
Medicated cosmetic compositions
|
|
US5358866A
(en)
|
1991-07-03 |
1994-10-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Cytosine deaminase negative selection system for gene transfer techniques and therapies
|
|
US5801029A
(en)
|
1993-02-16 |
1998-09-01 |
Onyx Pharmaceuticals, Inc. |
Cytopathic viruses for therapy and prophylaxis of neoplasia
|
|
FR2705361B1
(fr)
|
1993-05-18 |
1995-08-04 |
Centre Nat Rech Scient |
Vecteurs viraux et utilisation en thérapie génique.
|
|
KR100356615B1
(ko)
|
1993-07-13 |
2003-04-03 |
아방티 파르마 소시에테 아노님 |
결함아데노바이러스벡터및유전자치료에서그의사용
|
|
US5631236A
(en)
|
1993-08-26 |
1997-05-20 |
Baylor College Of Medicine |
Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
|
|
US5595756A
(en)
*
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
US5830686A
(en)
|
1994-01-13 |
1998-11-03 |
Calydon |
Tissue-specific enhancer active in prostate
|
|
US5677170A
(en)
|
1994-03-02 |
1997-10-14 |
The Johns Hopkins University |
In vitro transposition of artificial transposons
|
|
US5587299A
(en)
|
1994-04-20 |
1996-12-24 |
Memorial Sloan-Kettering Cancer Center |
Isolated nucleic acid molecule coding for fibroblast activation protein alpha and uses thereof
|
|
US7732129B1
(en)
|
1998-12-01 |
2010-06-08 |
Crucell Holland B.V. |
Method for the production and purification of adenoviral vectors
|
|
US5877011A
(en)
|
1996-11-20 |
1999-03-02 |
Genzyme Corporation |
Chimeric adenoviral vectors
|
|
CN1242051A
(zh)
|
1996-12-31 |
2000-01-19 |
昂尼克斯药物公司 |
用于肿瘤治疗和预防的致细胞病变病毒
|
|
US6420524B1
(en)
|
1997-02-20 |
2002-07-16 |
Johns Hopkins University School Of Medicine |
Gain of function mutations in ATP-dependent transposition proteins
|
|
JP2001519175A
(ja)
|
1997-10-09 |
2001-10-23 |
プロ − バイラス，インコーポレイテッド |
ウイルスを用いた新生物の処置
|
|
US20030044384A1
(en)
|
1997-10-09 |
2003-03-06 |
Pro-Virus, Inc. |
Treatment of neoplasms with viruses
|
|
US6291214B1
(en)
|
1998-05-11 |
2001-09-18 |
Glaxo Wellcome Inc. |
System for generating recombinant viruses
|
|
US20020019051A1
(en)
|
1998-05-27 |
2002-02-14 |
Monika Lusky |
Chimeric adenoviral vectors
|
|
US20030017138A1
(en)
|
1998-07-08 |
2003-01-23 |
Menzo Havenga |
Chimeric adenoviruses
|
|
CN1110553C
(zh)
|
1998-07-15 |
2003-06-04 |
杭州赛狮生物技术开发有限公司 |
基因工程腺病毒及其用途
|
|
US6455314B1
(en)
|
1998-09-11 |
2002-09-24 |
Genvec, Inc. |
Alternatively targeted adenovirus
|
|
PT1137792E
(pt)
|
1998-12-09 |
2007-08-10 |
Therion Biolog Corp |
Vector recombinado que exprime moléculas costimulantes múltiplas e as suas utilizações
|
|
DE60029195T2
(de)
|
1999-02-22 |
2007-06-28 |
Transgene S.A. |
Verfahren zur Gewinnung von purifizierter Virenzusammensetzung
|
|
CN1347450A
(zh)
|
1999-04-09 |
2002-05-01 |
阿文蒂斯药物股份有限公司 |
用于保存感染性重组腺病毒的组合物
|
|
DK1818408T3
(da)
|
1999-05-17 |
2011-10-17 |
Crucell Holland Bv |
Rekombinant adenovirus af serotypen Ad11
|
|
JP2003501041A
(ja)
|
1999-06-01 |
2003-01-14 |
ユニバーシティ オブ ワシントン |
細胞特異的な感染およびゲノム組み込みのためのキメラファイバータンパク質を発現する組換えアデノウイルスベクター
|
|
ATE403715T1
(de)
|
1999-08-09 |
2008-08-15 |
Targeted Genetics Corp |
Erhöhung der expression einer einzelsträngigen, heterologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen
|
|
US7396679B2
(en)
|
1999-11-15 |
2008-07-08 |
Onyx Pharmaceuticals, Inc. |
Oncolytic adenovirus
|
|
PT1252322E
(pt)
|
2000-01-21 |
2005-03-31 |
Biovex Ltd |
Estirpes de virus de herpes para terapia genica
|
|
US7456009B2
(en)
|
2000-03-07 |
2008-11-25 |
Merck & Co., Inc. |
Adenovirus formulations
|
|
JP2003534806A
(ja)
|
2000-05-31 |
2003-11-25 |
ジェンベク、インコーポレイティッド |
アデノウイルスベクターのターゲティングの方法および組成物
|
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
|
CA2412377A1
(en)
|
2000-06-06 |
2001-12-13 |
Bristol-Myers Squibb Company |
B7-related nucleic acids and polypeptides and their uses for immunomodulation
|
|
WO2002053759A1
(en)
|
2001-01-04 |
2002-07-11 |
Wadell Goeran |
Viral vector for gene therapy
|
|
US20050175589A1
(en)
|
2001-07-13 |
2005-08-11 |
Btg International Limited |
Anti-neoplastic viral agents
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
EP1327688A1
(en)
|
2002-01-14 |
2003-07-16 |
Vereniging Voor Christelijk Wetenschappelijk Onderwijs |
Adenoviruses with enhanced lytic potency
|
|
EP1470233A1
(en)
|
2002-02-01 |
2004-10-27 |
Transgene S.A. |
Adenoviral vectors for modulating the cellular activities associated with pods
|
|
US20060147420A1
(en)
|
2004-03-10 |
2006-07-06 |
Juan Fueyo |
Oncolytic adenovirus armed with therapeutic genes
|
|
US7858367B2
(en)
|
2002-04-30 |
2010-12-28 |
Duke University |
Viral vectors and methods for producing and using the same
|
|
US20040167088A1
(en)
|
2003-02-25 |
2004-08-26 |
Genvec, Inc. |
Method of using adenoviral vectors with increased persistence in vivo
|
|
WO2004087930A1
(en)
|
2003-03-28 |
2004-10-14 |
Saint Louis University |
Adenovirus replication-competent vectors expressing trail
|
|
US20050136035A1
(en)
|
2003-06-03 |
2005-06-23 |
Derek Ko |
Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
|
|
WO2005010149A2
(en)
|
2003-07-18 |
2005-02-03 |
Onyx Pharmaceuticals, Inc. |
Subgroup b adenoviral vectors for treating disease
|
|
JP4948174B2
(ja)
|
2003-10-16 |
2012-06-06 |
マイクロメット アクツィエン ゲゼルシャフト |
多重特異的脱免疫ｃｄ３−結合物質
|
|
WO2005107474A2
(en)
|
2004-04-30 |
2005-11-17 |
Introgen Therapeutics, Inc. |
Oncolytic adenovirus armed with therapeutic genes
|
|
CA2836987C
(en)
|
2004-05-26 |
2016-07-05 |
Psioxus Therapeutics Limited |
Chimeric adenoviruses for use in cancer treatment
|
|
US20060292682A1
(en)
|
2004-07-22 |
2006-12-28 |
Hawkins Lynda K |
Addition of transgenes into adenoviral vectors
|
|
WO2006039045A2
(en)
|
2004-09-01 |
2006-04-13 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adenoviral vectors able to transduce apcs, potential use in immune response generation
|
|
US20090208924A1
(en)
|
2004-12-01 |
2009-08-20 |
Bayer Schering Pharma Aktiengesellschaft |
Generation of Replication Competent Viruses for Therapeutic Use
|
|
WO2007027860A2
(en)
|
2005-08-31 |
2007-03-08 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccines
|
|
DE102005055128B4
(de)
|
2005-11-15 |
2015-04-02 |
Universität Rostock |
Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
|
|
ES2304281B1
(es)
|
2006-02-01 |
2009-08-12 |
Dnatrix Inc. |
Adenovirus oncoliticos para el tratamiento del cancer.
|
|
JP5448840B2
(ja)
|
2006-12-22 |
2014-03-19 |
プシオクサス・セラピューティクス・リミテッド |
腫瘍退縮アデノウイルスの作出およびその使用
|
|
US20110034560A1
(en)
|
2008-01-29 |
2011-02-10 |
Sven Jacobson |
Liquid formulations of compounds active at sulfonylurea receptors
|
|
US20110086005A1
(en)
|
2008-05-27 |
2011-04-14 |
Oncolytics Biotech Inc. |
Modulating interstitial pressure and oncolytic viral delivery and distribution
|
|
RU2547600C2
(ru)
*
|
2008-10-01 |
2015-04-10 |
Эмджен Рисерч (Мьюник) Гмбх |
Pscaxcd3, cd19xcd3, c-metxcd3, эндосиалинxcd3, epcamxcd3, igf-1rxcd3 или fap-альфаxcd3 биспецифическое одноцепочечное антитело с межвидовой специфичностью
|
|
CN101381742A
(zh)
|
2008-10-23 |
2009-03-11 |
浙江理工大学 |
晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用
|
|
ES2385251B1
(es)
|
2009-05-06 |
2013-05-06 |
Fundació Privada Institut D'investigació Biomèdica De Bellvitge |
Adenovirus oncolíticos para el tratamiento del cáncer.
|
|
US20100297072A1
(en)
|
2009-05-19 |
2010-11-25 |
Depinho Ronald A |
Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
|
|
JP2013506664A
(ja)
|
2009-10-02 |
2013-02-28 |
ルードヴィッヒ インスティテュート フォー キャンサー リサーチ リミテッド |
抗線維芽細胞活性化タンパク質抗体並びにその方法及び使用
|
|
EP2486137B1
(en)
|
2009-10-05 |
2018-05-30 |
Ya-Fang Mei |
Replication-competent ad11p based viral vectors
|
|
WO2012024351A2
(en)
|
2010-08-16 |
2012-02-23 |
Salk Institute For Biological Studies |
Adenoviral assembly method
|
|
WO2012038606A1
(en)
|
2010-09-24 |
2012-03-29 |
Oncos Therapeutics Oy |
Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies
|
|
PH12013502531A1
(en)
*
|
2011-08-23 |
2014-01-20 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
WO2013074507A2
(en)
|
2011-11-14 |
2013-05-23 |
Regenerative Sciences, Llc |
Suspended particle delivery systems and methods
|
|
CN102586327B
(zh)
|
2012-01-18 |
2013-09-11 |
陕西师范大学 |
一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用
|
|
CA2871711A1
(en)
|
2012-05-04 |
2013-11-07 |
Pfizer Inc. |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
|
WO2014138314A1
(en)
|
2013-03-05 |
2014-09-12 |
Baylor College Of Medicine |
Oncolytic virus
|
|
GB201322851D0
(en)
*
|
2013-12-23 |
2014-02-12 |
Psioxus Therapeutics Ltd |
Method
|
|
GB2519564A
(en)
|
2013-10-24 |
2015-04-29 |
Shared Band Ltd |
Multicast transmission over bonded broadband
|
|
GB201318793D0
(en)
|
2013-10-24 |
2013-12-11 |
Plaquetec Ltd |
Vascular Biomarkers
|
|
SI3021859T1
(en)
|
2013-10-25 |
2018-04-30 |
Psioxus Therapeutics Limited |
Oncolytic adenoviruses equipped with heterologous genes
|
|
KR20160137946A
(ko)
|
2013-11-22 |
2016-12-02 |
디엔에이트릭스, 인코포레이티드 |
면역 세포 자극성 수용체 작용제(들)를 발현하는 아데노바이러스
|
|
KR102380402B1
(ko)
|
2014-04-03 |
2022-03-31 |
아이쥐엠 바이오사이언스 인코포레이티드 |
변형된 j-사슬
|
|
GB201406608D0
(en)
*
|
2014-04-12 |
2014-05-28 |
Psioxus Therapeutics Ltd |
Virus
|
|
JP2017529070A
(ja)
|
2014-08-27 |
2017-10-05 |
サイオクサス セラピューティクス リミテッド |
アデノウイルスの製造方法
|
|
GB201503500D0
(en)
|
2015-03-02 |
2015-04-15 |
Ucl Business Plc |
Cell
|
|
WO2016146894A1
(en)
|
2015-03-17 |
2016-09-22 |
Tilt Biotherapeutics Oy |
Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto
|
|
US11000559B2
(en)
|
2015-04-30 |
2021-05-11 |
Psioxus Therapeutics Limited |
Oncolytic adenovirus encoding a B7 protein
|
|
CN108697745A
(zh)
|
2015-12-17 |
2018-10-23 |
皮斯奥克斯治疗公司 |
编码抗tcr复合体抗体或片段的b组腺病毒
|
|
EP3430148A4
(en)
|
2016-03-18 |
2020-01-01 |
Nantcell, Inc. |
MULTIMODAL VECTOR FOR DENDRITIC CELL INFECTION
|
|
IL303187A
(en)
|
2016-08-29 |
2023-07-01 |
Akamis Bio Ltd |
Adenovirus with bispecific T cell activator
|
|
GB201713765D0
(en)
|
2017-08-28 |
2017-10-11 |
Psioxus Therapeutics Ltd |
Modified adenovirus
|
|
EP3529361B1
(en)
|
2016-10-20 |
2021-03-24 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
WO2018083258A1
(en)
|
2016-11-03 |
2018-05-11 |
Psioxus Therapeutics Limited |
Oncolytic adenovirus encoding at least three transgenes
|
|
WO2018083257A1
(en)
|
2016-11-03 |
2018-05-11 |
Psioxus Therapeutics Limited |
Oncolytic adenovirus encoding transgenes
|
|
WO2018083259A1
(en)
|
2016-11-03 |
2018-05-11 |
Psioxus Therapeutics Limited |
Oncolytic adenovirus encoding transgenes
|
|
GB201801614D0
(en)
|
2018-01-31 |
2018-03-14 |
Psioxus Therapeutics Ltd |
Formulation
|